CSP
DGX icon

Cary Street Partners’s Quest Diagnostics DGX Stock Holding History

Cary Street Partners’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157K Buy
741
+159
+27% +$31.2K ﹤0.01% 964
2026
Q1 		$114K Buy
582
+20
+4% +$3.89K ﹤0.01% 893
2025
Q4 		$97.4K Sell
562
-40
-7% -$7.28K ﹤0.01% 907
2025
Q3 		$115K Sell
602
-544
-47% -$96.5K ﹤0.01% 857
2025
Q2 		$206K Sell
1,146
-366
-24% -$63.6K 0.01% 762
2025
Q1 		$256K Sell
1,512
-943
-38% -$155K 0.01% 684
2024
Q4 		$370K Buy
+2,455
New +$382K 0.01% 566

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Cary Street Partners's DGX Position: Q2 2026 in Review

Cary Street Partners increased its Quest Diagnostics (DGX) stake by 27% in Q2 2026, buying an estimated $31.2K and bringing the position to 741 shares worth $157K. The position accounts for ﹤0.01% of the portfolio, ranked #964.

Cary Street Partners first reported a position in DGX in Q4 2024 and has held it in 7 quarters since. The position peaked at $370K in Q4 2024. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Cary Street Partners held 741 shares of Quest Diagnostics worth $157K as of Q2 2026.
  • Cary Street Partners bought 159 Quest Diagnostics shares in Q2 2026, an estimated $31.2K.
  • Quest Diagnostics made up ﹤0.01% of Cary Street Partners's portfolio in Q2 2026, its #964 holding.
  • Cary Street Partners first reported a position in Quest Diagnostics in Q4 2024 and has held it in 7 quarters since.
  • Cary Street Partners's Quest Diagnostics position peaked at $370K in Q4 2024.
  • 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.